Risperidone extended release - Luye Pharma Group

Drug Profile

Risperidone extended release - Luye Pharma Group

Alternative Names: LY-03004; Risperidone ER microspheres - Luye Pharma Group

Latest Information Update: 28 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Luye Pharma Group
  • Class Antidepressants; Antineoplastics; Antipsychotics; Behavioural disorder therapies; Isoxazoles; Piperidines; Pyrimidinones; Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Bipolar disorders; Schizophrenia

Most Recent Events

  • 20 Jun 2018 Preregistration for Bipolar disorders in USA, Japan, European Union, China (IM)
  • 20 Jun 2018 Preregistration for Schizophrenia in Japan, China, European Union, USA (IM)
  • 06 Jun 2018 Luye Pharma plans to launch risperidone extended-release in China, European Union and USA in the second half of 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top